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Mucosal microbiota of intestinal 
polyps reveals putative biomarkers 
of colorectal cancer
Marta Mangifesta1, Leonardo Mancabelli1, Christian Milani  1, Federica Gaiani2, 
Nicola de’Angelis3, Gian Luigi de’Angelis2, Douwe van Sinderen4, Marco Ventura1,5 & 
Francesca Turroni1,5
The human intestine retains a complex microbial ecosystem, which performs crucial functions that 
impact on host health. Several studies have indicated that intestinal dysbiosis may impact on the 
establishment of life-threatening intestinal diseases such as colorectal cancer. An adenomatous polyp 
is the result of abnormal tissue growth, which is benign but is considered to be associated with a high 
risk of developing colorectal cancer, based on its grade of dysplasia. Development of diagnostic tools 
that are based on surveying the gut microbiota and are aimed at early detection of colorectal cancer 
represent highly desirable target. For this purpose, we performed a pilot study in which we applied a 
metataxonomic analysis based on 16S rRNA gene sequencing approach to unveil the composition of 
microbial communities of intestinal polyps. Moreover, we performed a meta-analysis involving the 
reconstructed microbiota composition of adenomatous polyps and publicly available metagenomics 
datasets of colorectal cancer. These analyses allowed the identification of microbial taxa such as 
Faecalibacterium, Bacteroides and Romboutsia, which appear to be depleted in cancerogenic mucosa 
as well as in adenomatous polyps, thus representing novel microbial biomarkers associated with early 
tumor formation. Furthermore, an absolute quantification of Fusubacterium nucleatum in polyps further 
compounded the important role of this microorganism as a valuable putative microbial biomarker for 
early diagnosis of colorectal cancer.
Adenomatous polyps or adenomas have long been recognized as precursors of colorectal cancer1,2. Colorectal 
cancer (CRC) is one of the most commonly diagnosed cancers worldwide and consequently one of the major 
causes of death in developed countries3. It is known that adenomatous polyps in some cases may evolve to 
colorectal cancer, even though no currently available scientific evidence unequivocally demonstrate in how many 
years and what are the precise causes of degeneration. So far there is a growing number of studies that highlight 
a direct correlation between polyp size, histology and progression of this pathology to CRC4. Furthermore, the 
molecular causes promoting such malignant transformation of polyps are essentially unknown5. Several factors 
have been investigated for polyp involvement in cancer development, such as genetics, epigenetics, diet, life style, 
obesity, alcohol intake and smoking6.
In recent decades, it has become evident that gut bacteria and their metabolites may participate in triggering 
or progression of colorectal cancer through various proposed mechanisms, including the production of reactive 
oxygen radicals and other genotoxins7–10, phenolic compound, and indole production11, as well as conversion 
of dietary factors into carcinogens and tumor promoters12, and induction of proinflammatory and procarcino-
genic pathways in host epithelial cells13–15. These proposed mechanisms have an impact in altering the metabolic 
environment of the host, which may directly or indirectly influence mutagenesis rates and thus carcinogenesis16. 
Various studies have explored the gut microbiota of individuals with CRC, resulting in the identification of a 
range of different bacterial groups being associated with carcinogenesis, including Helicobacter pylori, Bacteroides 
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fragilis, Fusobacterium nucleatum, various pathogenic Escherichia coli, Streptococcus gallolyticus and members of 
the genus Clostridium17–26. Although screening and lifestyle play important roles in early detection and preven-
tion of colorectal cancer, the identification of new diagnostic tools in particular for the early detection of tumors is 
important. Previous studies have compared the gut microbiota composition of stool samples from healthy people 
versus patient with polyps27,28. However, the fecal microbiota is only partially representing the autochthonous 
microbiota that is in direct contact with the intestinal mucosa29,30. Thus, in order to evaluate the role of the indige-
nous gut microbiota of subjects undergoing colic mucosectomies of polypoid lesions, we performed a pilot study 
collecting gut biopsies from healthy mucosa and polyps from the same subjects. On these samples, we performed 
a meta-analysis involving the here reconstructed microbiota composition of adenomatous polyps and publicly 
available metagenomic datasets of colorectal cancer based on 16S rRNA microbial profiling data31–33 in order to 
search for the occurrence of common microorganisms between polyps and colon cancer. Altogether, these analy-
ses revealed potential novel microbial biomarkers associated with early malignant transformation.
Materials and Methods
Patient recruitment within a pilot study. At the Gastroenterology and Digestive Endoscopy Unit, 
University Hospital of Parma, Italy, 12 patients were enrolled, after obtaining informed consent (Table S1). 
Exclusion criteria included age >of 90, absence of colic polyps in pancolonoscopy, use of antibiotics within the 
past 3 weeks, inability to sign informed consent. Colonic Mucosa with Polyp (CMP) and Healthy Marginal Tissue 
(HMT) were obtained from the same subject collected by endoscopy biopsy forceps, thus generating a total of 
24 samples (mean age of subjects: 66 ± 12 years old), immediately frozen at −80 °C and stored until further pro-
cessing for DNA extraction. DNA was extracted from each sample using the PowerViralTM Environmental RNA/
DNA Isolation Kit Sample (Qiagen) following the manufacturer’s instructions (Qiagen Ltd, Strasse, Germany). 
This study protocol was approved by Ethics Committee of Parma Province and all experiments were performed 
in accordance with relevant guidelines and regulations. Each patient was characterized by demographic data, level 
of disease indicators and therapy.
16S rRNA gene amplification. Partial 16S rRNA gene sequences were amplified from extracted DNA 
using primer pair Probio_Uni (5′-CCTACGGGRSGCAGCAG-3′)/Probio_Rev (5′-ATTACCGCGGCTGCT-3′), 
which targets the V3 region of the 16S rRNA gene sequence34. Illumina adapter overhang nucleotide sequences 
were then added to the partial 16S rRNA gene-specific amplicons, which in turn were further processed by 
employing the 16S Metagenomic Sequencing Library Preparation Protocol (Part #15044223 Rev. B – Illumina; 
see also below). Amplifications were carried out using a Verity Thermocycler (Applied Biosystems). The integrity 
of the PCR amplicons was analysed by electrophoresis on a 2200 TapeStation Instrument (Agilent Technologies, 
USA).
MiSeq sequencing of 16S rRNA Gene-based amplicons. PCR products obtained following the ampli-
fication of a section of the 16S rRNA gene were purified by a magnetic purification step involving Agencourt 
AMPure XP DNA purification beads (Beckman Coulter Genomics GmbH, Bernried, Germany) in order to 
remove primer dimers. The DNA concentration of the amplified sequence library was estimated employing a 
fluorimetric Qubit quantification system (Life Technologies). Amplicons were diluted to 4 nM and 5 µl of each 
diluted DNA amplicon sample was mixed to prepare the pooled final library. Paired-end sequencing (250 bp × 
2) was performed using an Illumina MiSeq sequencer with MiSeq Reagent Kit v3 chemicals-600 cycles (Illumina 
Inc., California, USA).
16S rRNA-microbial profiling analysis. The fastq files were processed using QIIME35 as previously 
described34. Paired-end reads were merged, and quality control implementation allowed the retention of 
sequences with a length between 140 and 400 bp, mean sequence quality score >25 and with truncation of a 
sequence at the first base if a low quality sequence within a rolling 10 bp window was found. Sequences with 
mismatched forward and/or reverse primers were omitted. 16S rRNA Operational Taxonomic Units (OTUs) 
were defined at ≥97% sequence homology using uclust36 and OTUs with less than 10 sequences were filtered. 
The Biological Observation Matrix (BIOM) obtained was analysed by summarize_taxa.py script in order to get 
the relative abundance of each taxonomic group for all samples. All reads were classified to the lowest possible 
taxonomic rank using QIIME35 and a reference dataset from the SILVA database37. The microbial richness of the 
samples (alpha-diversity) was evaluated with the Chao1 index through the alpha_rarefaction.py script included 
in the Qiime software suite using default parameters. Similarities between samples (beta-diversity) were calcu-
lated by unweighted uniFrac35,38. Hierarchical clusterings were performed with TMeV 4.8.1 (http://www.tm4.org) 
using Pearson correlation.
Statistical analyses. SPSS software (www.ibm.com/software/it/analytics/spss/) were used to complete sta-
tistical analysis. All data were presented as means ± SD. Furthermore, differential abundance of bacteria taxa and 
alpha-diversity were tested by one-way analysis of variance (ANOVA).
Quantitative -PCR. qPCR experiments were based on species-specific primers of Fusobacterium 
nucleatum targeting a previously described prostaglandin transporter-encoding gene39. The genome 
copy-number and the deduced cell number (since the genes targeted were in single copy per genome) was 
evaluated by comparing the cycle threshold (Ct) values obtained with those from a standard curve. Standard 
curves were calculated from serial dilutions of a culture with a known cell number (as determined by via-
ble count assessment) for the bacterial strain versus Ct produced for each target gene. The primer sequences 
were as follows: forward primer 5′-CAACCATTACTTTAACTCTACCATGTTCA-3′ and reverse primer 
5′-GTTGACTTTACAGAAGGAGATTATGTAAAAATC-3′. qPCR was performed using the CFX96 system 
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(BioRad, CA, USA). Each PCR reaction mix contained the following: 12.5 μl 2x SYBR SuperMix Green (BioRad, 
CA, USA), 1 μl of DNA dilution, each of the forward and reverse primers at 0.5 μM and nuclease-free water 
was added to obtain a final volume of 20 μl. PCR products were detected with SYBR Green fluorescent dye and 
amplified according to the following protocol: one cycle of 95 °C for 2 minutes, followed by 42 cycles of 95 °C for 
5 s and 60 °C for 30 s. Melting curve: 65 °C to 95 °C with increments of 0.5 °C/s. In each run, negative controls 
for each primer set were included. Cycle thresholding was calculated using the automated settings for Biorad 
CFX Manager 3.1 software (BioRad). The entire qPCR experiment was performed a second time using the same 
samples and methods as outlined above, for the purpose of replication, and very similar results were obtained.
Data Deposition. The 16S rRNA profiling data sequenced in this study were deposited in SRA database 
under accession number PRJNA415554.
Results and Discussion
Patients and pathological data. A total of twelve patients with polyps were included in this pilot study. 
From those, histological analyses revealed that four corresponded to adenomatous polyps and eight to hyperplas-
tic polyps. All adenomatous polyps were found in males, while the remaining hyperplastic polyps were collected 
from three males and five females. Two biopsies were collected from each patient, one corresponding to the polyp 
and one to healthy mucosa. Patient characteristics and details of endoscopic treatment performed are outlined 
in Table S1.
Cataloguing of polyp-associated microbiota and comparison to healthy mucosa microbi-
ota. Twelve Colonic Mucosa with Polyp (CMP) and corresponding Healthy Marginal Tissue (HMT) samples 
(i.e. total of 24 samples), retrieved from twelve hospitalized subjects, were used to evaluate the microbiota taxo-
nomic profile by means of 16S rRNA gene sequencing analysis as described previously34.
Next generation sequencing of these samples produced a total of 2,059,497 sequencing reads with an average 
of 85,812 reads per sample (Table S2). Subsequent quality and chimera filtering produced a total of 1,479,134 
filtered reads with an average of 61,631 reads, and ranging from 33,783 to 202,018 reads per sample (Table S2).
Rating of rarefaction curves based on the Chao1 biodiversity indexes calculated for the two subgroups of 
sequenced read pools showed that both curves tend to reach a plateau confirming the high accuracy of the per-
formed 16S rRNA profiling analysis. Furthermore, average rarefaction curves revealed a different trend of bac-
terial richness of the gut microbiota of healthy samples compared to that found in the polyp sample group, i.e. 
higher level of HMT vs CMP samples (Fig. S1). However, these analyses displayed no statistical significance, 
since the ANOVA calculated at the highest rarefaction depths reached by all the samples, i.e. Chao1 average is 
1895 ± 480 in HMT and 1678 ± 634 in CMP indicated a p-value > 0.05 (Fig. S1).
16S rRNA profiling of HMT and CMP samples. Inspection of predicted taxonomic profiles at phylum 
level for all samples showed that Firmicutes represented the dominant phylum (average of 57.59% ± 10.48%) of 
the colonic mucosa samples, out-numbering the Bacteroidetes (average of 9.24% ± 8.01%) and Proteobacteria 
(average of 10.26% ± 8.19%) phyla.
Nevertheless, no major shifts were observed in bacterial populations between healthy mucosa and 
Polyp-associated mucosa, although we did observe a moderate reduction of Actinobacteria (relative percentage 
difference of −13.43%) and Bacteroides (relative percentage difference of −1.02%) in CMP and a concomitant 
modest increase of Firmicutes (relative percentage difference of 2.84%) compared to HMT (Fig. 1a–c).
Furthermore, at genus level, we identified 308 genera of which 225 appear to be present in at least one sample 
of HMT and CMP groups. In detail, 35 bacterial taxa were present in all 24 samples, thus representing the mucosa 
core microbiota, i.e. the permanent and common members of the microbial community40, which may include 
specific species important for the maintenance of an efficiently functioning gut ecosystem41 (Fig. 1b).
Moreover, HMT displayed 29 unique taxa representing the 0.015% of the total genera abundance, while CMP 
showed 19 unique representing 0.008% of the total genera abundance (Fig. 1b).
Taxa associated with HMT and CMP. In order to further identify differences in microbiota composi-
tion between CMP and HMT patients, we focused on 30 taxa, which were shown to be present as the absolute 
change of >±0.1% or that displayed a significant variation in terms of relative abundance (p-value < 0.05). In 
this context, these 30 taxa varied in terms of relative abundance, encompassing an increase ranging from 10% 
(Lachnoclostridium) to 641% (Romboutsia), or a decrease ranging from −16% (Ruminococcaceae UCG-002) to 
−74% (Ruminococcus I) in HMT datasets compared to those obtained from CMP samples (Fig. 1c). Interestingly, 
members of the Actinobacteria phylum such as the Bifidobacterium genus are present in higher abundance in 
HMT as compared to CMP samples. Bifidobacteria species are known to represent typical gut microorganisms 
with presumed positive effects on human health and recently their absence has been linked to various disease con-
ditions42–45. In addition, the Faecalibacterium genus, which is among bacteria with purported health-promoting 
activities46, as well as Bacteroides taxa, which have been found at a lower abundance in IBD patients47 are present 
at a higher level in HMT samples. Moreover, Romboutsia taxa is the genus with the highest relative abundance in 
HMT vs. CMP samples. Notably, Romboutsia is a recently described bacterial genus48,49 commonly identified in 
the human gut50,51, and often associated with a healthy status of patients50,51. The drastic reduction of members of 
this particular genus (−86,51%) in mucosa associated with polyps may represent a potential microbial indicator 
of a disease condition50.
In contrast, the higher presence of Helicobacter and Klebsiella, which are typically associated with carcino-
genesis52,53 in CMP samples reflect a typical disease condition. Interestingly, among taxa showing a significant 
variation in terms of relative abundance (p-value < 0.05), Unclassified member (U. m.) of Peptostreptococcaceae 
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family occurs with an increased relative abundance of 337.30% in HMT vs. CMP samples, while Peptoclostridium 
is totally absent in all analyzed CMP samples.
In order to integrate and confirm the observed differences in relative abundance between HMT and CMP 
samples, we defined the trend (increase or decrease) for each bacterial taxa in healthy subjects versus polyp con-
dition. Considering all patiens, we identified that only the genus Romboutsia displayed the same trend in at least 
80% of HMT samples, while all taxa trend of CMP were <75%. These results reinforce the notion that Romboutsia 
may play a key role in maintaining the health status of the host and render this taxon a very valuable candidate as 
biomarker of intestinal dysbiosis.
Identification of possible cancer biomarkers. In order to reinforce our taxonomical observation and to 
enlarge the CMP database, we performed a survey and selection of 16S rRNA-based polyp-associated metagen-
omic datasets deposited in the publicly NCBI database. However, the published polyp-associated metagenomic 
datasets are based on fecal samples27,28. In this context, it is worth mentioning that previous studies on healthy 
patients or children with rectal bleeding indicated that fecal and mucosal samples belonging to the same individ-
ual displayed a very dissimilar microbial composition29,30. It has been reported that, based on different statistical 
analyses, fecal and mucosal samples cluster separately, at family and species taxonomic level29,30. To circumvent 
the issue of absence of data from polyp-associated biopsies, we decided to use human CRC datasets. In fact, as 
discussed above, CRC has been considered to represent a later stage of adenomas2,54. Consequently, we retrieved 
293 samples from the four publically available CRC BioProjects31–33 (Table S3). In detail, we selected the datasets 
based on Illumina or 454 technologies including both healthy and CRC samples obtained from biopsies collected 
from the human large intestine (Table S3). Notably, to avoid biases caused by different bioinformatic analyses 
pipelines55, the sequence reads pools of each study were analyzed involving the same custom script56 based on the 
QIIME software suite35 used here for the 24 HMT/CMP samples. These datasets were enriched with the CMP and 
HMT 16S rRNA microbial profiling data obtained and described in our current study.
Evaluation of the difference between all Healthy Tissue (HT) and CRC-polyps Tissue (CpT) samples high-
lighted 38 genera with a p-value < 0.05 calculated thought Analysis of variance (ANOVA) (Fig. 2). Furthermore, 
we investigated the difference between each case-control, HT vs. CRC and HMT vs. CMP, in order to calculate 
the trend percentage.
Association of ANOVA and trend percentage analyses indicated that CpT samples had a higher abundance of 
genera belonging to Proteobacteria and Fusobacteria phyla, specifically Campylobacter (taxonomic trend prev-
alence of 100% in CpT) and Fusobacterium (taxonomic trend prevalence of 60% in CpT) compared to healthy 
samples (Fig. 3). Interestingly, these taxa are commonly found in patients with CRC57, with the Fusobacterium 
genus frequently being associated with tumor progression58. Moreover, CpT samples possessed microbial genera 
commonly involved in development of intestinal disease or pathologies, such as Streptococcus (taxonomic trend 
prevalence of 80.00% in CpT) and Gemella (taxonomic trend prevalence of 80% in CpT)59,60. In contrast, HT 
samples showed higher abundance of ‘beneficial’ bacterial genera, as well as U. m. of Lachnospiraceae family and 
Faecalibacterium (taxonomic trend prevalence of 100% in HT), Bacteroides (taxonomic trend prevalence of 80% 
in HT), and Romboutsia (taxonomic trend prevalence of 60% in HT) compared to CpT.
Figure 1. Exploration of the diversity in HMT and CMP groups. Panel a represents a bar plot of the bacterial 
phyla identified in the 24 analyzed samples. Panel b depicts a Venn diagram illustrating the total, unique and 
shared number of OTUs predicted for HMT and CMP datasets. Panel c shows the variation in terms of relative 
abundance of >0.4%, and showing either an increase of >10% or decrease of <−16% in CMP data sets as 
compared to those obtained from HMT samples.
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Furthermore, focusing on genera with a taxonomic trend with a prevalence of 100% and a significant p-value 
(<0.05) calculated between HT and CpT (Fig. 3), it was possible to identify five taxa characteristic of HT and 
one taxon of CpT subjects. In detail, healthy samples showed high abundance of U. m. of Lachnospiraceae fam-
ily, Lachnoclostridium, Faecalibacterium, Ruminiclostridium and Subdoligranulum, while disease-associated CpT 
samples showed high abundance of Campylobacter. These results reflect the assumption that genera belonging 
to Lachnospiraceae and Ruminococcaceae families may protect healthy subjects from intestinal disease61, such as 
through the production of short-chain fatty acids (SCFAs)62. In contrast, the higher abundance of bacteria belong-
ing to Campylobacter genus may confirm its correlation with the development of gastrointestinal diseases63,64.
Overall, we found a correspondence between the trend that we retrieved in our HMT vs CMP samples, and 
that of the HT vs CRC samples, revealing a small number of microbial taxa that could be considered as bacterial 
biomarkers for early detection of tumor or, conversely, reflecting a healthy condition.
Quantification of Fusobacterium nucleatum by qPCR. Since several studies associated the presence 
of Fusobacterium nucleatum with a formation and progression of colorectal cancer39,64–67 the relative abundances 
of this species were measured by qPCR in all 24 samples (HTM and CMP biopsies of 12 patients). Notably qPCR 
analyses displayed that this bacterium has been found in six patients (i.e., 2, 5, 6, 7, 9 and 13) with a genome 
copy number ranging from 2.24E1 to 1.25E3 for the HTM samples, and a genome copy number range of 2.08E2 
to 3.26E3 for CMP biopsies (Fig. 4). These data clearly indicated that the total load of Fusobacterium nucleatum 
was significantly (p-value < 0.04) higher for samples 5, 6, 7 and 9 in the CMP vs. HMT mucosa for each patient. 
Interestingly, sample 13, showed a total load of Fusobacterium nucleatum higher respect all other samples, i.e., a 
mean value of 1.02E3 for the HMT as compared to a mean value of 2.37E3 for the CMP (p-value < 0.04) (Fig. 4). 
These preliminary data suggest that this species can, as previously indicated, not only be considered an important 
bacterial biomarker for the diagnosis of colorectal cancer39,66, but may also serve as a putative valuable microbial 
biomarker for early diagnosis of malignant displacement of polyps.
Conclusions
Recent findings have shown that intestinal diseases are correlated with microbiota alterations such as in the case 
of ulcerative colitis45,68.
The contribution of gastrointestinal microbiota in the progression and development of colorectal cancer is 
complex and not fully understood67, but previous in vivo murine based-analyses highlight the potential role of 
many individual bacteria to promote carcinogenesis28,69.
In the current pilot study, we compared bacterial population in mucosa samples of patients with polyps or 
CRC, versus healthy mucosa, showing that the Romboutsia genus is more abundant in healthy compared to 
Figure 2. Exploration of the diversity in HT and CpT groups. The image shows the variation in terms of relative 
abundance of HT and CpT samples. Only taxa with a p-vale <0.05 were shown.
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Figure 3. Evaluation of taxa trend in the gut microbiota of HT and CpT samples. Asterisks indicate statistically 
significant differences between each case-control for all five datasets (P-value <0.05). The heatmap shows the 
taxonomic trend of each 16S rRNA gene-based metagenomic dataset. Names of identified bacterial taxa are 
listed on the left, while names of sample groups used are listed at the top. Healthy Marginal Tissue (HMT); 
Colonic Mucosa with Polyps(CMP); ColoRectal Cancer (CRC); all Healthy Tissue (HT) and CRC-polyps Tissue 
(CpT). The green color represents high abundance in healthy cases, red color represents high abundance in 
disease cases and black color represents the absence of the bacterial taxa. Columns show the studies analyzed 
and rows indicate the bacterial taxonomy at genus level.
www.nature.com/scientificreports/
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polyp-associated tissue. Remarkably, the relative abundance of Romboutsia in CRC tissue was found to be dras-
tically reduced. Thus, we may argue that the absence of this microbial genus is a first indicator of an alteration of 
the mucosa. Remarkably, this microbial taxon has already been observed for other gut-associated diseases49–51.
Interestingly, the Peptoclostridium genus was undetectable in all CMP sample tested, while analysis of the 
HMT samples revealed a relatively high number of U. m. of Peptostreptococcaceae family.
Our findings were in line with the findings of a meta-analysis in which we compared the CMP samples with 
CRC samples from publically available metagenomic datasets31–33. Our metagenomic analysis revealed that CpT 
samples had a higher abundance of the Fusobacteria phylum compared to healthy samples. Interestingly, the 
Fusobacterium genus is often involved in tumor progression58,70.
At genus level, we identified five taxa characteristic of HT and one taxon typical of CpT subjects. In detail, 
healthy samples were shown to contain a high abundance of U. m. of Lachnospiraceae family, Lachnoclostridium, 
Faecalibacterium, Ruminiclostridium and Subdoligranulum, while CpT samples showed high abundance of 
Campylobacter. The higher abundance of bacteria belonging to the Campylobacter genus in CRC mucosa, as well 
as polyp-associated samples reinforces its correlation with the development of intestinal pathologies63,64. On the 
other hand, genera belonging to Lachnospiraceae and Ruminococcaceae families appear to be correlated to bene-
ficial effects on the host as described previously61.
Gut microbiota include a very complex array of microorganisms and its compositional changes have been 
shown to impact on human health status71,72. The identification of microbial players that are distinctly altered in 
their abundance in CRC-associated samples may allow early diagnosis of malignant transformation as well as the 
identification of protective bacteria missing in polyps or CRC tissue.
In conclusion, the data obtained in this pilot study have allowed us to identify possible microbial biomarkers 
associated with polyps and/or CRC. However, such findings need further validation by analysis of a larger num-
ber of samples, in order to further substantiate and fully characterize such potential microbial biomarkers of CRC 
development, as well as beneficial bacteria, and to identify their functions and interactions with the host.
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